Thomas J. Herzfeld Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,000	Closed	-$61.9K	–	325
2023 Q3	$61.9K	Hold	4,000	–	–	0.02%	118
2023 Q2	$62.8K	Hold	4,000	–	–	0.03%	110
2023 Q1	$65.9K	Hold	4,000	–	–	0.03%	97
2022 Q4	$62.4K	Hold	4,000	–	–	0.03%	105
2022 Q3	$52K	Hold	4,000	–	–	0.02%	101
2022 Q2	$56K	Hold	4,000	–	–	0.02%	110
2022 Q1	$57K	Hold	4,000	–	–	0.02%	118
2021 Q4	$55K	Hold	4,000	–	–	0.02%	139
2021 Q3	$66K	Hold	4,000	–	–	0.03%	123
2021 Q2	$67K	Hold	4,000	–	–	0.03%	132
2021 Q1	$73K	Hold	4,000	–	–	0.03%	135
2020 Q4	$73K	Hold	4,000	–	–	0.03%	133
2020 Q3	$62K	Hold	4,000	–	–	0.04%	91
2020 Q2	$73K	Sell	4,000 -279	-7%	-$5.01K	0.04%	121
2020 Q1	$65K	Hold	4,279	–	–	0.03%	119
2019 Q4	$84K	Hold	4,279	–	–	0.03%	120
2019 Q3	$74K	Sell	4,279 -117	-3%	-$2.02K	0.03%	137
2019 Q2	$78K	Buy	4,396 +396	+10%	+$7.21K	0.03%	145
2019 Q1	$81K	Hold	4,000	–	–	0.03%	162
2018 Q4	$67K	Buy	+4,000	New	+$67.5K	0.03%	166

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Thomas J. Herzfeld Advisors's TAK Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 4,000 shares — an estimated $61.9K sold.

Thomas J. Herzfeld Advisors first reported a position in TAK in Q4 2018 and held it in 20 quarters. The position peaked at $84K in Q4 2019. 306 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 4,000 Takeda Pharmaceutical shares in Q4 2023, an estimated $61.9K.
Thomas J. Herzfeld Advisors first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 20 quarters.
Thomas J. Herzfeld Advisors's Takeda Pharmaceutical position peaked at $84K in Q4 2019.
306 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.